表紙
市場調查報告書

醫療設備CRO(開發業務委託機構)市場:第2版(2020年∼2030年)

Medical Device CROs Market (2nd Edition), 2020 - 2030

出版商 ROOTS ANALYSIS 商品編碼 936004
出版日期 內容資訊 英文 405 Pages
商品交期: 最快1-2個工作天內
價格
醫療設備CRO(開發業務委託機構)市場:第2版(2020年∼2030年) Medical Device CROs Market (2nd Edition), 2020 - 2030
出版日期: 2020年04月30日內容資訊: 英文 405 Pages
簡介

全球的醫療設備市場在2020年約有4,500億美元的規模同時預估未來數年間會持續成長。醫療設備生產公司對於臨床研究開發的實施所需要的資源與專門技術知識包括資金上的困難,因而將醫療設備開發業務包含臨床研究與藥品管理的大部分業務都交給CRO(開發業務委託機構)的情況逐漸增加。

見解案例

本報告是針對全球的醫療設備CRO市場調查並提供市場規模、動向與機會、按照治療領域或事業規模或設備等級或提供臨床服務種類或服務地區區別的市場分析、競爭情況、主要企業概論等情報資訊。

目錄

第1章 導論

  • 調查範圍
  • 調查方法
  • 各章概要

第2章 執行摘要

第3章 導論

  • 本章概要
  • 醫療設備概要
    • 醫療設備歷史與進化
    • 醫療設備分類
  • 開發業務委託機構(CRO)概要
    • CRO的進展
  • 醫療設備產業中CRO的角色
  • 醫療設備CRO種類
  • CRO可提供的服務種類
  • CRO的醫藥業務外包優勢
  • 醫藥業務外包的風險與課題
  • 選擇適合的CRO夥伴的考慮層面

第4章 現在市場情勢

  • 本章概要
  • 臨床服務提供商
  • 臨床前服務提供商
  • 獨立服務提供商
    • 按照成立年區別
    • 按照公司規模區別
    • 按照總公司所在區別
    • 按照公司規模與總公司所在區別
    • 按照提供服務種類區別

第5章 法規與贖回情況

  • 本章概要
  • 醫療設備的法規與贖回情況守則
  • 北美
  • 歐洲
  • 亞太地區
  • 各地法規制度的比較
  • 結論

第6章 企業概要資料

  • 本章概要
  • Avania (Formerly known as Factory CRO)
  • Charles River Laboratories
  • Clinlogix
  • CROMSOURCE
  • CSSi LifeSciences
  • Eurofins Medical device Testing
  • genae
  • IMARC Research
  • IQVIA
  • Medpace
  • NAMSA
  • Qserve Group
  • Regulatory and Clinical Research Institute (現Covance)
  • WuXi AppTec

第7章 醫療設備開發者與CRO的關係:促成重大銷售的因素和績效指標

  • 本章概要
  • 關鍵績效指標(KPI)的定義與重要性
  • KPI評價因素的主要考慮內容
  • KPI的種類
  • KPI比較
  • 結論

第8章 競爭基準

  • 本章概要
  • 調查方法
  • 基準分析:同行小組
    • 北美:同行小組I
    • 北美:同行小組II
    • 北美:同行小組III
    • 歐洲:同行小組IV
    • 歐洲:同行小組V
    • 亞太地區:同行小組VI
    • 亞太地區:同行小組VII

第9章 主要企業的品牌與地位

  • 本章概要
  • 調查範圍與手法
  • FMD K&L
  • ICON
  • NAMSA
  • Parexel International
  • PPD

第10章 臨床試驗分析

  • 本章概要
  • 調查範圍與手法
  • 醫療設備:臨床試驗
  • 按發起人類型分析
  • 醫療設備:備案患者組

第11章 合併與收購

  • 本章概要
  • 合併與收購模式
  • 醫療設備CRO:合併與收購

第12章 調查發現

第13章 市場規模與預測

  • 本章概要
  • 預測範圍與手法
  • 醫療設備CRO市場:2020年∼2030年
    • 按治療領域區別
    • 按事業規模區別
    • 按設備等級區別
    • 按臨床服務提供商區別
    • 按臨床前服務提供商區別
    • 按地域區別
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第14章 案例學習:新冠肺炎造成的影響

  • 本章概要
  • 新冠肺炎對於醫療設備產業的影響
    • 短期影響
    • 長期影響
  • 未來戰略與計畫:俯瞰圖

第15章 SWOT分析

第16章 動向與機會

  • 本章概要
  • 預測連接設備數量的增加
  • 採用數據分析和實時監控解決方案
  • 對雲端計算和存儲解決方案的需求
  • 越來越多的現實證據需要監管部門批准
  • 結論

第17章 訪談概要

第18章 附錄1:圖表數據

第19章 附錄2:企業與組織名單

目錄

Example Insights:

Overview:

According to the Food and Drug Administration's Center for Devices and Radiological Health (CDRH), at present, there are close to 175,000 types of medical devices available in the US. In fact, since 2019, the USFDA has approved close to 55 medical devices. Further, over 7,000 medical device focused clinical trials have been registered worldwide. In this context, our estimates suggest that total revenues from global sales of medical devices is likely to be around USD 450 billion in 2020. The medical devices market currently represents a large segment of the healthcare industry and is projected to continue to grow over the coming years. However, only a limited proportion of device developers claim to have the necessary resources and technical expertise to develop and conduct clinical research, in-house. This is mostly attributed to the high cost of acquiring the necessary infrastructure / capabilities for such research initiatives, making it difficult for companies with limited finances to undertake and manage elaborate R&D initiatives by themselves. In addition, regulations governing the review (of safety and efficacy) and approval of such devices are gradually becoming more stringent. For instance, the EU's revised Medical Device Regulation (MDR) have rendered medical devices subject to rigorous quality assessments, necessitating a certain type of expertise and affiliated resources. Although the COVID-19 pandemic has delayed the enforcement of these guidelines to May 2021, device developers still need to establish the necessary means to address this upcoming challenge. In this regard, outsourcing has been shown to offer a number of benefits, including cost savings and expediting time to market. As a result, medical device developers are now increasingly outsourcing significant parts of their respective clinical research efforts and regulatory affairs management to contract research organizations (CROs).

The medical device CRO market is highly fragmented, featuring the presence of well-established players (which contribute to a majority share of the overall revenues), mid-sized firms and a number of new entrants, offering niche expertise. In fact, over 50 medical device focused CROs have been established since 2010. It is worth noting that, in order to cope with modern day challenges, CROs have adopted emerging technologies / operating principles, such as big data analysis, artificial intelligence (AI) and real-world evidence, and are gradually working towards improving their approach to research. For this purpose, many traditional CROs have established strategic business relations with information technology (IT) and data management solutions providers. In addition, this industry has witnessed significant merger and acquisition activity in the last ten years, with several smaller businesses being acquired in efforts to grow the service portfolios / capabilities of more established firms. According to experts, the medical device CRO industry is anticipated to witness a similar growth trajectory as that of the pharmaceutical CRO market, in the coming 5-10 years.

Scope of the Report:

The 'Medical Device CROs Market (2nd Edition), 2020-2030' report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices. The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers (consulting, training, quality assurance, clinical operations, and regulatory affairs management).
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
  • Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices. Each profile features an overview of the company, along with information on year of establishment, number of employees, location of headquarters, presence across key geographies, target therapeutic areas, financial details (if available), medical device focused service portfolio, and an informed future outlook.
  • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
  • A competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different device classes.
  • A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices, along with information on number of registered trials, location of trial site, current status of trials, current phase of trial, type of sponsor, target therapeutic area(s) and number of patients enrolled.
  • A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020, highlighting geographical activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall medical device CRO industry.
  • An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.

One of the key objectives of this report was to evaluate the existing market size and the future growth potential within the medical device CROs domain. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] different phases of development (clinical and preclinical) [B] types of clinical services offered (clinical trial management, data management, regulatory affairs management, consulting and others) [C] types of preclinical services (biocompatibility testing, sterility and microbiology testing, material characterization and analytical services and others) [D] device class (class I, class II and class III), and [E] target therapeutic area (bone disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, ophthalmic disorders, pain management, respiratory disorders, sleeping disorders and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth. In addition, the report discusses the impact of the recent COVID-19 pandemic on the overall medical device industry, along with providing details related to the future market opportunity for medical device CROs.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following stakeholders:

  • Lajos Sarosi, Chief Executive Officer and Co-founder, HungaroTrial
  • Christian Wolflehner, Managing Director, Clinical Trial Specialist, CW Research & Management
  • Troy Mccall, Chief Operating Officer, CROMSOURCE
  • Nazish Urooj, Senior manager, Medical & Clinical Operations, Metrics Research
  • Alexa Foltin-Mertgen, Business Development Manager, AtoZ-CRO
  • Tania Persson, Business Development Manager, A+ Science
  • C. Omprakash, Technical Director and Partner, Vyomus Consulting
  • Anonymous

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the medical device CROs market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a brief introduction to medical devices, highlighting key historical and development milestones, and classification of such devices. It also provides a general overview of the concept of CROs, featuring a discussion on the historical evolution of contract research services market in the medical device domain. Further, the chapter presents details related to the various types of CROs that operate within the medical device market and the different types of services they usually offer. It further lists the advantages as well as challenges associated with outsourcing medical device research and clinical operations to contract service providers, along with the key parameters that need to be considered while selecting a CRO partner.

Chapter 4 provides a detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and training), [B] preclinical service providers (consulting, biocompatibility testing, materials characterization and analytical testing, preclinical trials support, sterility testing and microbiology testing, and training) and [C] stand-alone service providers (consulting, training, quality assurance, clinical operations, and regulatory affairs management).

Chapter 5 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), and Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

Chapter 6 features detailed profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices. Each profile features an overview of the company, along with information on year of establishment, number of employees, location of headquarters, presence across key geographies, target therapeutic area, financial details (if available), medical device focused service portfolio, and an informed future outlook.

Chapter 7 features an analysis on the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain, based on information gathered via secondary research (for top-ten medical device players), as well as credible inputs from primary research.

Chapter 8 presents a competitive benchmarking of the various players engaged in this domain. It highlights the capabilities of small-sized, mid-sized and large companies in terms of their expertise in medical device services. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups and providing a means for stakeholders to identify ways to gain a competitive advantage in the industry.

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio) highlighting the current perceptions regarding their proprietary brands across different device classes.

Chapter 10 presents a detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices, along with information on number of registered trials, location of trial site, current status of trials, current phase of trial, type of sponsor, target therapeutic area(s) and number of patients enrolled.

Chapter 11 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2015-2020, based on parameters such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, type of company and key value drivers. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.

Chapter 12 presents insights from the survey conducted for this study. We invited over 200 stakeholders that provide CRO services to medical device developers. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services, prevalent trends and associated commercial potential of this domain.

Chapter 13 presents a likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different phases of development (clinical and preclinical) [B] types of clinical services offered (clinical trial management, data management, regulatory affairs management, consulting and others) [C] types of preclinical services (biocompatibility testing, sterility and microbiology testing, material characterization and analytical services and others) [D] device class (class I, class II and class III), and [E] target therapeutic area (bone disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, ophthalmic disorders, pain management disorders, respiratory disorders, sleeping disorders and others), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 14 highlights the effect of coronavirus outbreak on the global medical device industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for CROs. In addition, it includes a brief section on strategies and action plans that medical device companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 15 provides a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall medical devices CRO industry.

Chapter 16 presents a discussion on the upcoming opportunities / trends of medical device contract services market that are likely to impact the future evolution of this domain over the coming years. These include (but not limited to) growth in number of connected devices, adoption of data analytics and real-time monitoring solutions, growing need for cloud-based data storage solutions and introduction of real-world evidence.

Chapter 17 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented the details of interviews held with Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial), Troy Mccall (Chief Operating Officer, CROMSOURCE), Christian Wolflehner (Managing Director, Clinical Trial Specialist, CW Research & Management), Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research), Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO), Tania Persson (Business Development Manager, A+ Science) and C. Omprakash (Technical Director and Partner, Vyomus Consulting) and Anonymous.

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Medical Devices
    • 3.2.1. Historical Evolution of Medical Devices
    • 3.2.2. Classification of Medical Devices
  • 3.3. Overview of Contract Research Organizations (CROs)
    • 3.3.1. Evolution of CROs
  • 3.4. Role of CROs in the Medical Device Industry
  • 3.5. Types of Medical Device CROs
  • 3.6. Types of Services Offered by CROs
  • 3.7. Advantages of Outsourcing Drug Discovery Operations to CROs
  • 3.8. Risks and Challenges Associated with Outsourcing
  • 3.9. Key Considerations for Selecting a Suitable CRO Partner

4. MEDICAL DEVICE CROS: CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Medical Device CROs: Clinical Service Providers
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Type of Service Offered
  • 4.3. Medical Device CROs: Preclinical Service Providers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Company Size and Location of Headquarters
    • 4.3.5. Analysis by Type of Service Offered
  • 4.4. Medical Device CROs: Standalone Service Providers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Location of Headquarters
    • 4.4.4. Analysis by Company Size and Location of Headquarters
    • 4.4.5. Analysis by Type of Service Offered

5. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

  • 5.1. Chapter Overview
  • 5.2. General Regulatory and Reimbursement Guidelines for Medical Devices
  • 5.3. Regulatory and Reimbursement Landscape in North America
    • 5.3.1. The US Scenario
      • 5.3.1.1. Regulatory Authority
      • 5.3.1.2. Review / Approval Process
      • 5.3.1.3. Reimbursement Landscape
        • 5.3.1.3.1. Payer Mix
        • 5.3.1.3.2. Reimbursement Process
    • 5.3.2. The Canadian Scenario
      • 5.3.2.1. Regulatory Authority
      • 5.3.2.2. Review / Approval Process
      • 5.3.2.3. Reimbursement Landscape
        • 5.3.2.3.1. Payer Mix
        • 5.3.2.3.2. Reimbursement Process
    • 5.3.3. The Mexican Scenario
      • 5.3.3.1. Regulatory Authority
      • 5.3.3.2. Review / Approval Process
      • 5.3.3.3. Reimbursement Landscape
        • 5.3.3.3.1. Payer Mix
  • 5.4. Regulatory and Reimbursement Landscape in Europe
    • 5.4.1. Overall Scenario
      • 5.4.1.1. Overall Regulatory Authority
      • 5.4.1.2. Overall Review / Approval Process
    • 5.4.2. The UK Scenario
      • 5.4.2.1. Regulatory Authority
      • 5.4.2.2. Review / Approval Process
      • 5.4.2.3. Reimbursement Landscape
        • 5.4.2.3.1. Payer Mix
        • 5.4.2.3.2. Reimbursement Process
    • 5.4.3. The French Scenario
      • 5.4.3.1. Regulatory Authority
      • 5.4.3.2. Review / Approval Process
      • 5.4.3.3. Reimbursement Landscape
        • 5.4.3.3.1. Payer Mix
        • 5.4.3.3.2. Reimbursement Process
    • 5.4.4. The German Scenario
      • 5.4.4.1. Regulatory Authority
      • 5.4.4.2. Review / Approval Process
      • 5.4.4.3. Reimbursement Landscape
        • 5.4.4.3.1. Payer Mix
        • 5.4.4.3.2. Reimbursement Process
    • 5.4.5. The Italian Scenario
      • 5.4.5.1. Regulatory Authority
      • 5.4.5.2. Review / Approval Process
      • 5.4.5.3. Reimbursement Landscape
        • 5.4.5.3.1. Payer Mix
        • 5.4.5.3.2. Reimbursement Process
    • 5.4.6. The Spanish Scenario
      • 5.4.6.1. Regulatory Authority
      • 5.4.6.2. Review / Approval Process
      • 5.4.6.3. Reimbursement Landscape
        • 5.4.6.3.1. Payer Mix
        • 5.4.6.3.2. Reimbursement Process
  • 5.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
    • 5.5.1. The Australian Scenario
      • 5.5.1.1. Regulatory Authority
      • 5.5.1.2. Review / Approval Process
      • 5.5.1.3. Reimbursement Landscape
        • 5.5.1.3.1. Payer Mix
        • 5.5.1.3.2. Reimbursement Process
    • 5.5.2. The Brazilian Scenario
      • 5.5.2.1. Regulatory Authority
      • 5.5.2.2. Review / Approval Process
      • 5.5.2.3. Reimbursement Landscape
        • 5.5.2.3.1. Payer Mix
        • 5.5.2.3.2. Reimbursement Process
    • 5.5.3. The Chinese Scenario
      • 5.5.3.1. Regulatory Authority
      • 5.5.3.2. Review / Approval Process
      • 5.5.3.3. Reimbursement Landscape
        • 5.5.3.3.1. Payer Mix
        • 5.5.3.3.2. Reimbursement Process
    • 5.5.4. The Indian Scenario
      • 5.5.4.1. Regulatory Authority
      • 5.5.4.2. Review / Approval Process
      • 5.5.4.3. Reimbursement Landscape
        • 5.5.4.3.1. Payer Mix
    • 5.5.5. The Israeli Scenario
      • 5.5.5.1. Regulatory Authority
      • 5.5.5.2. Review / Approval Process
      • 5.5.5.3. Reimbursement Landscape
        • 5.5.5.3.1. Payer Mix
    • 5.5.6. The Japanese Scenario
      • 5.5.6.1. Regulatory Authority
      • 5.5.6.2. Review / Approval Process
      • 5.5.6.3. Reimbursement Landscape
        • 5.5.6.3.1. Payer Mix
        • 5.5.6.3.2. Reimbursement Process
    • 5.5.7. The New Zealand Scenario
      • 5.5.7.1. Regulatory Authority
      • 5.5.7.2. Review / Approval Process
      • 5.5.7.3. Reimbursement Landscape
        • 5.5.7.3.1. Payer Mix
        • 5.5.7.3.2. Reimbursement Process
    • 5.5.8. The Singapore Scenario
      • 5.5.8.1. Regulatory Authority
      • 5.5.8.2. Review / Approval Process
      • 5.5.8.3. Reimbursement Landscape
        • 5.5.8.3.1. Payer Mix
        • 5.5.8.3.2. Reimbursement Process
    • 5.5.9. The South Korean Scenario
      • 5.5.9.1. Regulatory Authority
      • 5.5.9.2. Review / Approval Process
      • 5.5.9.3. Reimbursement Landscape
        • 5.5.9.3.1. Payer Mix
        • 5.5.9.3.2. Reimbursement Process
    • 5.5.10. The South African Scenario
      • 5.5.10.1. Regulatory Authority
      • 5.5.10.2. Review / Approval Process
      • 5.5.10.3. Reimbursement Landscape
    • 5.5.11. The Taiwan Scenario
      • 5.5.11.1. Regulatory Authority
      • 5.5.11.2. Review / Approval Process
      • 5.5.11.3. Reimbursement Landscape
        • 5.5.11.3.1. Payer Mix
        • 5.5.11.3.2. Reimbursement Process
    • 5.5.12. The Thailand Scenario
      • 5.5.12.1. Regulatory Authority
      • 5.5.12.2. Review / Approval Process
      • 5.5.12.3. Reimbursement Landscape
  • 5.6. Comparison of Regional Regulatory Control
  • 5.7. Concluding Remarks

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Avania (Formerly known as Factory CRO)
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
    • 6.2.3. Future Outlook
  • 6.3. Charles River Laboratories
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Future Outlook
  • 6.4. Clinlogix
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
    • 6.4.3. Future Outlook
  • 6.5. CROMSOURCE
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
    • 6.5.3. Future Outlook
  • 6.6. CSSi LifeSciences
    • 6.6.1. Company Overview
    • 6.6.2. Service Portfolio
    • 6.6.3. Future Outlook
  • 6.7. Eurofins Medical device Testing
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Future Outlook
  • 6.8. genae
    • 6.8.1. Company Overview
    • 6.8.2. Service Portfolio
    • 6.8.3. Future Outlook
  • 6.9. IMARC Research
    • 6.9.1. Company Overview
    • 6.9.2. Service Portfolio
    • 6.9.3. Future Outlook
  • 6.10. IQVIA
    • 6.10.1. Company Overview
    • 6.10.2. Service Portfolio
    • 6.10.3. Future Outlook
  • 6.11. Medpace
    • 6.11.1. Company Overview
    • 6.11.2. Service Portfolio
    • 6.11.3. Future Outlook
  • 6.12. NAMSA
    • 6.12.1. Company Overview
    • 6.12.2. Service Portfolio
    • 6.12.3. Future Outlook
  • 6.13. Qserve Group
    • 6.13.1. Company Overview
    • 6.13.2. Service Portfolio
    • 6.13.3. Future Outlook
  • 6.14. Regulatory and Clinical Research Institute (Now a part of Covance)
    • 6.14.1. Company Overview
    • 6.14.2. Service Portfolio
    • 6.14.3. Future Outlook
  • 6.15. WuXi AppTec
    • 6.15.1. Company Overview
    • 6.15.2. Service Portfolio
    • 6.15.3. Future Outlook

7. MEDICAL DEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS

  • 7.1. Chapter Overview
  • 7.2. Definition and Importance of Key Performance Indicators (KPIs)
  • 7.3. Key Considerations for Selection of KPIs
  • 7.4. Types of KPIs
    • 7.4.1. Financial Indicators
      • 7.4.1.1. Most Important KPIs
        • 7.4.1.1.1. Financial Stability
        • 7.4.1.1.2. Cost of Services Offered
        • 7.4.1.1.3. Comparative Analysis of Financial Indicators
      • 7.4.1.2. Industry Perspective
        • 7.4.1.2.1. Sponsors' (Big Pharma) Perspective
        • 7.4.1.2.2. Contract Service Providers' Perspective
    • 7.4.2. Process and Capability Indicators
      • 7.4.2.1. Most Important KPIs
        • 7.4.2.1.1. Proximity to Sponsor
        • 7.4.2.1.2. Capability to Innovate / Mitigate Risk
        • 7.4.2.1.3. Strength of Service Portfolio
        • 7.4.2.1.4. Comparative Analysis of Process / Capability Indicators
      • 7.4.2.2. Industry Perspective
        • 7.4.2.2.1. Sponsors' (Big Pharma) Perspective
        • 7.4.2.2.2. Contract Service Providers' Perspective
    • 7.4.3. Market Reputation Indicators
      • 7.4.3.1. Most Important KPIs
        • 7.4.3.1.1. Flexibility / Adaptability
        • 7.4.3.1.2. Time Management
        • 7.4.3.1.3. Quality / Reliability
        • 7.4.3.1.4. Regulatory Compliance / Track Record
        • 7.4.3.1.5. Comparative Analysis of Market Reputation Indicators
      • 7.4.3.2. Industry Perspective
        • 7.4.3.2.1. Sponsors' (Big Pharma) Perspective
        • 7.4.3.2.2. Contract Service Providers' Perspective
  • 7.5. Comparison of Key Performance Indicators
  • 7.6. Concluding Remarks

8. COMPETITIVE BENCHMARKING

  • 8.1. Chapter Overview
  • 8.2. Methodology
  • 8.3. Benchmark Analysis: Peer Groups
    • 8.3.1. North America, Peer Group I
    • 8.3.2. North America, Peer Group II
    • 8.3.3. North America, Peer Group III
    • 8.3.4. Europe, Peer Group IV
    • 8.3.5. Europe, Peer Group V
    • 8.3.6. Asia Pacific, Peer Group VI
    • 8.3.7. Asia Pacific, Peer Group VII

9. BRAND POSITIONING OF KEY INDUSTRY PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Brand Positioning Matrix: FMD K&L
  • 9.4. Brand Positioning Matrix: ICON
  • 9.5. Brand Positioning Matrix: NAMSA
  • 9.6. Brand Positioning Matrix: PAREXEL International
  • 9.7. Brand Positioning Matrix: PPD

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Medical Devices: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Phase
    • 10.3.4. Analysis by Therapeutic Area
    • 10.3.5. Analysis by Geography
    • 10.3.6. Geographical Analysis by Trial Status
  • 10.4. Analysis by Type of Sponsor
  • 10.5. Medical Devices: Analysis of Enrolled Patient Population
    • 10.5.1. Analysis by Trial Registration Year
    • 10.5.2. Analysis by Trial Status
    • 10.5.3. Analysis by Trial Phase
    • 10.5.4. Analysis by Therapeutic Area
    • 10.5.5. Analysis by Location of Trial Site

11. MERGERS AND ACQUISITIONS

  • 11.1. Chapter Overview
  • 11.2. Merger and Acquisition Models
  • 11.3. Medical Device CROs: Mergers and Acquisitions
    • 11.3.1. Analysis by Year of Merger / Acquisition
    • 11.3.2. Analysis by Type of Merger / Acquisition
    • 11.3.3. Regional Analysis
      • 11.3.3.1. Continent-wise Distribution
      • 11.3.3.2. Intercontinental and Intracontinental Deals
      • 11.3.3.3. Country-wise Distribution
    • 11.3.4. Ownership Change Matrix
    • 11.3.5. Analysis by Type of Company
    • 11.3.6. Analysis by Key Value Drivers
      • 11.3.6.1. Analysis by Key Value Drivers and Year of Acquisition

12. SURVEY INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. Designation of Respondents
  • 12.3. Type of Service Offered
  • 12.4. Target Therapeutic Area
  • 12.5. Number of Annual Projects
  • 12.6. Market Opportunity

13. MARKET SIZING AND FORECAST

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Forecast Methodology
  • 13.3. Overall Medical Device CRO Market, 2020-2030
    • 13.3.1. Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area
    • 13.3.2. Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation
    • 13.3.3. Medical Device CRO Market, 2020-2030: Distribution by Device Class
    • 13.3.4. Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered
    • 13.3.5. Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Servce Offered
    • 13.3.6. Medical Device CRO Market, 2020-2030: Distribution by Geography
  • 13.4. Medical Device CRO Market in North America, 2020-2030
    • 13.4.1. Medical Device CRO Market in North America, 2020-2030: Distribution by Therapeutic Area
      • 13.4.1.1. Medical Device CRO Market for Bone Disorders in North America, 2020-2030
      • 13.4.1.2. Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030
      • 13.4.1.3. Medical Device CRO Market for CNS Disorders in North America, 2020-2030
      • 13.4.1.4. Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030
      • 13.4.1.5. Medical Device CRO Market for Oncological Disorders in North America, 2020-2030
      • 13.4.1.6. Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030
      • 13.4.1.7. Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030
      • 13.4.1.8. Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030
      • 13.4.1.9. Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030
      • 13.4.1.10. Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030
    • 13.4.2. Medical Device CRO Market in North America, 2020-2030: Distribution by Device Class
      • 13.4.2.1. Medical Device CRO Market for Class I Devices in North America, 2020-2030
      • 13.4.2.2. Medical Device CRO Market for Class II Devices in North America, 2020-2030
      • 13.4.2.3. Medical Device CRO Market for Class III Devices in North America, 2020-2030
    • 13.4.3. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Clinical Service Offered
      • 13.4.3.1. Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030
      • 13.4.3.2. Medical Device CRO Market for Consulting Services in North America, 2020-2030
      • 13.4.3.3. Medical Device CRO Market for Data Management Services in North America, 2020-2030
      • 13.4.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030
      • 13.4.3.5. Medical Device CRO Market for Other Clinical Services in North America, 2020-2030
    • 13.4.4. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Preclinical Service Offered
      • 13.4.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030
      • 13.4.4.2. Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030
      • 13.4.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030
      • 13.4.4.4. Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030
  • 13.5. Medical Device CRO Market in Europe, 2020-2030
    • 13.5.1. Medical Device CRO Market in Europe, 2020-2030: Distribution by Therapeutic Area
      • 13.5.1.1. Medical Device CRO Market for Bone Disorders in Europe, 2020-2030
      • 13.5.1.2. Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030
      • 13.5.1.3. Medical Device CRO Market for CNS Disorders in Europe, 2020-2030
      • 13.5.1.4. Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030
      • 13.5.1.5. Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030
      • 13.5.1.6. Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030
      • 13.5.1.7. Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030
      • 13.5.1.8. Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030
      • 13.5.1.9. Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030
      • 13.5.1.10. Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030
    • 13.5.2. Medical Device CRO Market in Europe, 2020-2030: Distribution by Device Class
      • 13.5.2.1. Medical Device CRO Market for Class I Devices in Europe, 2020-2030
      • 13.5.2.2. Medical Device CRO Market for Class II Devices in Europe, 2020-2030
      • 13.5.2.3. Medical Device CRO Market for Class III Devices in Europe, 2020-2030
    • 13.5.3. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Clinical Service Offered
      • 13.5.3.1. Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030
      • 13.5.3.2. Medical Device CRO Market for Consulting Services in Europe, 2020-2030
      • 13.5.3.3. Medical Device CRO Market for Data Management Services in Europe, 2020-2030
      • 13.5.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030
      • 13.5.3.5. Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030
    • 13.5.4. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Preclinical Service Offered
      • 13.5.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030
      • 13.5.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030
      • 13.5.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030
      • 13.5.4.4. Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030
  • 13.6. Medical Device CRO Market in Asia-Pacific, 2020-2030
    • 13.6.1. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Therapeutic Area
      • 13.6.1.1. Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.2. Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.3. Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.4. Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.5. Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.6. Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.7. Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.8. Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.9. Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030
      • 13.6.1.10. Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
    • 13.6.2. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Device Class
      • 13.6.2.1. Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030
      • 13.6.2.2. Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030
      • 13.6.2.3. Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030
    • 13.6.3. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Clinical Service Offered
      • 13.6.3.1. Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030
      • 13.6.3.2. Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030
      • 13.6.3.3. Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030
      • 13.6.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030
      • 13.6.3.5. Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030
    • 13.6.4. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Preclinical Service Offered
      • 13.6.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030
      • 13.6.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030
      • 13.6.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030
      • 13.6.4.4. Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030
  • 13.7. Medical Device CRO Market in Rest of the World, 2020-2030
    • 13.7.1. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Therapeutic Area
      • 13.7.1.1. Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030
      • 13.7.1.2. Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030
      • 13.7.1.3. Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030
      • 13.7.1.4. Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030
      • 13.7.1.5. Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030
      • 13.7.1.6. Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030
      • 13.7.1.7. Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030
      • 13.7.1.8. Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030
      • 13.7.1.9. Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030
      • 13.7.1.10. Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030
    • 13.7.2. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Device Class
      • 13.7.2.1. Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030
      • 13.7.2.2. Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030
      • 13.7.2.3. Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030
    • 13.7.3. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Clinical Service Offered
      • 13.7.3.1. Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030
      • 13.7.3.2. Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030
      • 13.7.3.3. Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030
      • 13.7.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030
      • 13.7.3.5. Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030
    • 13.7.4. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Preclinical Service Offered
      • 13.7.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030
      • 13.7.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030
      • 13.7.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030
      • 13.7.4.4. Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

  • 14.1. Chapter Overview
  • 14.2. Impact of Coronavirus Upsurge on Medical Device Industry
    • 14.2.1. Short Term Impact
    • 14.2.2. Long Term Impact
  • 14.3. Future Strategies and Action Plans: A Bird's Eye View

15. SWOT ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Strengths
  • 15.3. Weaknesses
  • 15.4. Opportunities
  • 15.5. Threats
  • 15.6. Concluding Remarks

16. FUTURE TRENDS AND OPPORTUNITIES

  • 16.1. Chapter Overview
  • 16.2. Anticipated Growth in Number of Connected Devices
  • 16.3. Adoption of Data Analytics and Real-Time Monitoring Solutions
  • 16.4. Need for Cloud-based Computing and Storage Solutions
  • 16.5. Growing Need for Real World Evidence for Regulatory Approval
  • 16.6. Concluding Remarks

17. INTERVIEW TRANSCRIPTS

  • 17.1. Chapter Overview
  • 17.2. Lajos Sarosi, Chief Executive Officer and Co-founder, HungaroTrial
  • 17.3. Troy McCall, Chief Operating Officer, CROMSOURCE
  • 17.4. Christian Wolflehner, Managing Director and Clinical Trial Specialist, CW Research & Management
  • 17.5. Nazish Urooj, Senior manager, Medical & Clinical Operations, Metrics Research
  • 17.6. Alexa Foltin-Mertgen, Business Development Manager, AtoZ-CRO
  • 17.7. Tania Persson, Business Development Manager, A+ Science
  • 17.8. C. Omprakash, Technical Director and Partner, Vyomus Consulting
  • 17.9. Anonymous

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Historical Timeline of Medical Device Inventions
  • Figure 3.2 Medical Device: Development Process and Timeline
  • Figure 3.3 Type of CROs Engaged in the Medical Device Market
  • Figure 3.4 Services Offered by CROs
  • Figure 3.5 Risks / Challenges Associated with Outsourcing Operations to CROs
  • Figure 4.1 Medical Device Clinical CROs: Distribution by Year of Establishment
  • Figure 4.2 Medical Device Clinical CROs: Distribution by Company Size
  • Figure 4.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
  • Figure 4.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
  • Figure 4.5 Medical Device Clinical CROs: Distribution by Type of Service Offered
  • Figure 4.6 Medical Device Clinical CROs: Distribution by Year of Establishment, Type of Service Offered and Location of Headquarters
  • Figure 4.7 Medical Device Clinical CROs: Distribution by Types of Clinical Trial Management Services Offered
  • Figure 4.8 Medical Device Clinical CROs: Distribution by Types of Regulatory Services Offered
  • Figure 4.9 Medical Device Preclinical CROs: Distribution by Year of Establishment
  • Figure 4.10 Medical Device Preclinical CROs: Distribution by Company Size
  • Figure 4.11 Medical Device Preclinical CROs: Distribution by Location of Headquarters
  • Figure 4.12 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
  • Figure 4.13 Medical Device Preclinical CROs: Distribution by Type of Service Offered
  • Figure 4.14 Medical Device Standalone CROs: Distribution by Year of Establishment
  • Figure 4.15 Medical Device Standalone CROs: Distribution by Company Size
  • Figure 4.16 Medical Device Standalone CROs: Distribution by Location of Headquarters
  • Figure 4.17 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
  • Figure 4.18 Medical Device Standalone CROs: Distribution by Type of Service Offered
  • Figure 5.1 Key Regulatory Authorities for Medical Devices
  • Figure 5.2 Medical Devices Review / Approval Process in the US
  • Figure 5.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
  • Figure 5.4 Medical Devices National Coverage Determination Process in the US
  • Figure 5.5 Medical Devices Review / Approval Process in Canada
  • Figure 5.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
  • Figure 5.7 Medical Devices Review / Approval Process in Mexico
  • Figure 5.8 Regulatory Bodies in EU5 Countries
  • Figure 5.9 Steps involved in CE Marking Process
  • Figure 5.10 Medical Devices Review / Approval Process in Europe
  • Figure 5.11 Medical Devices Review / Approval Process in the UK
  • Figure 5.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
  • Figure 5.13 Reimbursement Process for Medical Devices in the UK
  • Figure 5.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
  • Figure 5.15 Reimbursement Process for Medical Devices through List of Products and Services Qualifying for Reimbursement
  • Figure 5.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
  • Figure 5.17 Reimbursement Process for In-Patient Setting in Germany
  • Figure 5.18 Reimbursement Process for Out-Patient Care in Germany
  • Figure 5.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
  • Figure 5.20 Reimbursement Process for Medical Devices in Italy
  • Figure 5.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
  • Figure 5.22 Reimbursement Process for Medical Devices in Spain
  • Figure 5.23 Medical Devices Review / Approval Process in Australia
  • Figure 5.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
  • Figure 5.25 Medical Devices Review / Approval Process in Brazil
  • Figure 5.26 Reimbursement Process for Medical Devices in Brazil
  • Figure 5.27 Medical Devices Review / Approval Process in China
  • Figure 5.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
  • Figure 5.29 Reimbursement Approval Process for Medical Devices in Shanghai
  • Figure 5.30 Medical Devices Review / Approval Process in India
  • Figure 5.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
  • Figure 5.32 Medical Devices Review / Approval Process in Japan
  • Figure 5.33 Snapshot of the Regulatory and Reimbursement Process in Japan
  • Figure 5.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
  • Figure 5.35 Reimbursement Process for New Medical Devices in Japan
  • Figure 5.36 Medical Devices Review / Approval Process in New Zealand
  • Figure 5.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
  • Figure 5.38 Medical Devices Review / Approval Process in Singapore
  • Figure 5.39 Medical Devices Review / Approval Process in South Korea
  • Figure 5.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
  • Figure 5.41 Medical Devices Review / Approval Process in South Africa
  • Figure 5.42 Medical Devices Review / Approval Process in Taiwan
  • Figure 5.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
  • Figure 5.44 Medical Devices Review / Approval Process in Thailand
  • Figure 5.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
  • Figure 5.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
  • Figure 6.1 Avania: Service Portfolio
  • Figure 6.2 Charles River Laboratories: Service Portfolio
  • Figure 6.3 Clinlogix: Service Portfolio
  • Figure 6.4 CROMSOURCE: Service Portfolio
  • Figure 6.5 CSSi LifeSciences: Service Portfolio
  • Figure 6.6 Eurofins Medical Device Testing: Service Portfolio
  • Figure 6.7 genae: Service Portfolio
  • Figure 6.8 IMARC Research: Service Portfolio
  • Figure 6.9 IQVIA: Service Portfolio
  • Figure 6.10 Medpace: Service Portfolio
  • Figure 6.11 NAMSA: Service Portfolio
  • Figure 6.12 Qserve Group: Service Portfolio:
  • Figure 6.13 Regulatory and Clinical Research Institute: Service Portfolio
  • Figure 6.14 WuXi AppTec: Service Portfolio
  • Figure 7.1 Key Attributes for Selection of Key Performance Indicators (KPIs)
  • Figure 7.2 Types of KPIs
  • Figure 7.3 Financial Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
  • Figure 7.4 Financial Indicators: Sponsors' (Big Pharma) Perspective
  • Figure 7.5 Financial Indicators: Contract Service Providers' Perspective
  • Figure 7.6 Process / Capability Indicators: Comparative Analysis of KPIs considered by Big Pharma Companies
  • Figure 7.7 Process / Capability Indicators: Sponsors' (Big Pharma) Perspective
  • Figure 7.8 Process / Capability Indicators: Contract Service Providers' Perspective
  • Figure 7.9 Market Reputation Indicators: Comparative Analysis of KPIs conssidered by Big Pharma Companies
  • Figure 7.10 Market Reputation Indicators: Sponsors' (Big Pharma) Perspective
  • Figure 7.11 Market Reputation Indicators: Contract Service Providers' Perspective
  • Figure 7.12 Comparison of Key Factors to be considered while selecting KPIs for Medical Devices
  • Figure 8.1 Competitive Benchmarking: Distribution by Region and Company Size
  • Figure 8.2 Competitive Benchmarking: North America, Peer Group I
  • Figure 8.3 Competitive Benchmarking: North America, Peer Group II
  • Figure 8.4 Competitive Benchmarking: North America, Peer Group III
  • Figure 8.5 Competitive Benchmarking: Europe, Peer Group IV
  • Figure 8.6 Competitive Benchmarking: Europe, Peer Group V
  • Figure 8.7 Competitive Benchmarking: Asia-Pacific, Peer Group VI
  • Figure 8.8 Competitive Benchmarking: Asia-Pacific, Peer Group VII
  • Figure 8.9 Competitive Benchmarking: Comparison of Services and Capabilities across Different Peer Groups
  • Figure 9.1 Brand Positioning of Key Industry Players
  • Figure 9.2 Brand Positioning Matrix: FMD K&L
  • Figure 9.2 Brand Positioning Matrix: ICON
  • Figure 9.3 Brand Positioning Matrix: NAMSA
  • Figure 9.4 Brand Positioning Matrix: PAREXEL International
  • Figure 9.5 Brand Positioning Matrix: PPD
  • Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2020
  • Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.4 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.5 Clinical Trial Analysis: Distribution by Geography
  • Figure 10.6 Clinical Trial Analysis: Geographical Distribution by Trial Status
  • Figure 10.7 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 10.8 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 10.9 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Figure 10.10 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 10.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
  • Figure 10.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
  • Figure 10.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Location of Trial Site
  • Figure 11.1 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2020)
  • Figure 11.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Figure 11.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
  • Figure 11.4 Mergers and Acquisitions: Continent-wise Distribution
  • Figure 11.5 Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Figure 11.6 Mergers and Acquisitions: Country-wise Distribution
  • Figure 11.7 Mergers and Acquisitions: Ownership Change Matrix
  • Figure 11.8 Mergers and Acquisitions: Distribution by Type of Company
  • Figure 11.9 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 11.10 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Figure 12.1 Survey Insights: Distribution of Respondents by Company Size
  • Figure 12.2 Survey Insights: Distribution of Respondents by Location of Company Headquarters
  • Figure 12.3 Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Figure 12.4 Survey Insights: Distribution of Respondents by Type of Service Offered
  • Figure 12.5 Survey Insights: Distribution of Respondents by Therapeutic Area
  • Figure 12.6 Survey Insights: Distribution of Respondents by Average Number of Projects
  • Figure 12.7 Survey Insights: Distribution of Respondents by Market Opportunity
  • Figure 13.1 Overall Medical Device CRO Market, 2020-2030 (USD Billion)
  • Figure 13.2 Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area (USD Billion)
  • Figure 13.3 Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
  • Figure 13.4 Medical Device CRO Market, 2020-2030: Distribution by Device Class (USD Billion)
  • Figure 13.5 Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered (USD Billion)
  • Figure 13.6 Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Service Offered (USD Billion)
  • Figure 13.7 Medical Device CRO Market, 2020-2030: Distribution by Geography (USD Billion)
  • Figure 13.8 Medical Device CRO Market in North America, 2020-2030 (USD Billion)
  • Figure 13.9 Medical Device CRO Market for Bone Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.10 Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.11 Medical Device CRO Market for CNS Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.12 Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.13 Medical Device CRO Market for Oncological Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.14 Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.15 Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.16 Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.17 Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030 (USD Billion)
  • Figure 13.18 Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030 (USD Billion)
  • Figure 13.19 Medical Device CRO Market for Class I Devices in North America, 2020-2030 (USD Billion)
  • Figure 13.20 Medical Device CRO Market for Class II Devices in North America, 2020-2030 (USD Billion)
  • Figure 13.21 Medical Device CRO Market for Class III Devices in North America, 2020-2030 (USD Billion)
  • Figure 13.22 Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030 (USD Billion)
  • Figure 13.23 Medical Device CRO Market for Consulting Services in North America, 2020-2030 (USD Billion)
  • Figure 13.24 Medical Device CRO Market for Data Management Services in North America, 2020-2030 (USD Billion)
  • Figure 13.25 Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030 (USD Billion)
  • Figure 13.26 Medical Device CRO Market for Other Clinical Services in North America, 2020-2030 (USD Billion)
  • Figure 13.27 Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030 (USD Billion)
  • Figure 13.28 Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030 (USD Billion)
  • Figure 13.29 Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030 (USD Billion)
  • Figure 13.30 Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030 (USD Billion)
  • Figure 13.31 Medical Device CRO Market in Europe, 2020-2030 (USD Billion)
  • Figure 13.32 Medical Device CRO Market for Bone Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.33 Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.34 Medical Device CRO Market for CNS Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.35 Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.36 Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.37 Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.38 Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.39 Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.40 Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030 (USD Billion)
  • Figure 13.41 Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030 (USD Billion)
  • Figure 13.42 Medical Device CRO Market for Class I Devices in Europe, 2020-2030 (USD Billion)
  • Figure 13.43 Medical Device CRO Market for Class II Devices in Europe, 2020-2030 (USD Billion)
  • Figure 13.44 Medical Device CRO Market for Class III Devices in Europe, 2020-2030 (USD Billion)
  • Figure 13.45 Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.46 Medical Device CRO Market for Consulting Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.47 Medical Device CRO Market for Data Management Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.48 Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.49 Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.50 Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.51 Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.52 Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.53 Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030 (USD Billion)
  • Figure 13.54 Medical Device CRO Market in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.55 Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.56 Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.57 Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.58 Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.59 Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.60 Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.61 Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.62 Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.63 Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.64 Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.65 Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.66 Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.67 Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.68 Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.69 Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.70 Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.71 Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.72 Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.73 Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.74 Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.75 Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.76 Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.77 Medical Device CRO Market in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.78 Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.79 Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.80 Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.81 Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.82 Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.83 Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.84 Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.85 Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.86 Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.87 Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.88 Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.89 Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.90 Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.91 Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.92 Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.99 Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.94 Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.95 Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.96 Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.97 Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.98 Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.99 Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030 (USD Billion)
  • Figure 14.1 Summary of Likely Impact of Coronavirus Pandemic on Medical Device Industry
  • Figure 15.1 Medical Device CRO Market: SWOT Analysis
  • Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 16.1 Future Trends and Opportunities for Medical Device CROs

List Of Tables

  • Table 3.1 Comparison of Key Factors Considered by Medical Device Developers for Selecting a CRO Partner: Harvey Ball Analysis
  • Table 4.1 Medical Device CROs: List of Clinical Service Providers
  • Table 4.2 Medical Device Clinical CROs: Information on Type of Service Offered
  • Table 4.3 Medical Device Clinical CROs: Information on Type of Clinical Trial Management Service Offered
  • Table 4.4 Medical Device Clinical CROs: Information on Type of Regulatory Service Offered
  • Table 4.5 Medical Device CROs: List of Preclinical Service Providers
  • Table 4.6 Medical Device Preclinical CROs: Information on Type of Service Offered
  • Table 4.7 Medical Device CROs: List of Standalone Service Providers
  • Table 5.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
  • Table 5.2 Device Classification: US
  • Table 5.3 Device Classification: Canada
  • Table 5.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
  • Table 5.5 Device Classification: Mexico
  • Table 5.6 Device Classification: Europe
  • Table 5.7 List of CE Directives in Europe
  • Table 5.8 Conformity Assessment Modules in Europe
  • Table 5.9 Device Classification: Australia
  • Table 5.10 Reimbursement and Pricing Approval Process of Medical devices in Australia
  • Table 5.11 Device Classification: Brazil
  • Table 5.12 Device Classification: China
  • Table 5.13 Device Classification: India
  • Table 5.14 Device Classification: Japan
  • Table 5.15 Medical Devices Reimbursement Categories
  • Table 5.16 Device Classification: New Zealand
  • Table 5.17 Device Classification: Singapore
  • Table 5.18 Device Classification: South Korea
  • Table 5.19 Device Classification: South Africa
  • Table 5.20 Device Classification: Thailand
  • Table 5.21 Medical Devices Regulatory Landscape Summary
  • Table 5.22 Medical Devices Reimbursement Landscape Summary
  • Table 6.1 Avania: Company Overview
  • Table 6.2 Avania: Future Outlook
  • Table 6.3 Charles River Laboratories: Company Overview
  • Table 6.4 Charles River Laboratories: Future Outlook
  • Table 6.5 Clinlogix: Company Overview
  • Table 6.6 Clinlogix: Future Outlook
  • Table 6.7 CROMSOURCE: Company Overview
  • Table 6.8 CROMSOURCE: Future Outlook
  • Table 6.9 CSSi Life Sciences: Company Overview
  • Table 6.10 Eurofins Medical Device Testing: Company Overview
  • Table 6.11 Eurofins Medical Device Testing: Future Outlook
  • Table 6.12 genae: Company Overview
  • Table 6.13 genae: Future Outlook
  • Table 6.14 IMARC Research: Company Overview
  • Table 6.15 IMARC Research: Future Outlook
  • Table 6.16 IQVIA: Company Overview
  • Table 6.17 IQVIA: Future Outlook
  • Table 6.18 Medpace: Company Overview
  • Table 6.19 Medpace: Future Outlook
  • Table 6.20 NAMSA: Company Overview
  • Table 6.21 NAMSA: Future Outlook
  • Table 6.22 Qserve Group: Company Overview
  • Table 6.23 Qserve Group: Future Outlook
  • Table 6.24 Regulatory and Clinical Research Institute: Company Overview
  • Table 6.25 Regulatory and Clinical Research Institute (Now a part of Covance): Future Outlook
  • Table 6.26 WuXi AppTec: Company Overview
  • Table 6.27 WuXi AppTec: Future Outlook
  • Table 8.1 Benchmark Analysis: Peer Groups
  • Table 11.1 Medical Device CRO Market: List of Mergers and Acquisitions, 2015-2020
  • Table 11.2 Acquisitions: Key Value Drivers
  • Table 12.1 Survey Insights: Overview of Respondents
  • Table 12.2 Survey Insights: Designation and Seniority Level of Respondents
  • Table 12.3 Survey Insights: Type of Service Offered
  • Table 12.4 Survey Insights: Therapeutic Area
  • Table 12.5 Survey Insights: Average Number of Projects
  • Table 12.6 Survey Insights: Market Opportunity
  • Table 18.1 Medical Device Clinical CROs: Distribution by Year of Establishment
  • Table 18.2 Medical Device Clinical CROs: Distribution by Company Size
  • Table 18.3 Medical Device Clinical CROs: Distribution by Location of Headquarters
  • Table 18.4 Medical Device Clinical CROs: Distribution by Company Size and Location of Headquarters
  • Table 18.5 Medical Device Clinical CROs: Distribution by Type of Service Offered
  • Table 18.6 Medical Device Clinical CROs: Distribution by Year of Establishment, Type of Service Offered and Location of Headquarters
  • Table 18.7 Medical Device Clinical CROs: Distribution by Types of Clinical Trial Management Services Offered
  • Table 18.8 Medical Device Clinical CROs: Distribution by Types of Regulatory Services Offered
  • Table 18.9 Medical Device Preclinical CROs: Distribution by Year of Establishment
  • Table 18.10 Medical Device Preclinical CROs: Distribution by Company Size
  • Table 18.11 Medical Device Preclinical CROs: Distribution by Location of Headquarters
  • Table 18.12 Medical Device Preclinical CROs: Distribution by Company Size and Location of Headquarters
  • Table 18.13 Medical Device Preclinical CROs: Distribution by Type of Service Offered
  • Table 18.14 Medical Device Standalone CROs: Distribution by Year of Establishment
  • Table 18.15 Medical Device Standalone CROs: Distribution by Company Size
  • Table 18.16 Medical Device Standalone CROs: Distribution by Location of Headquarters
  • Table 18.17 Medical Device Standalone CROs: Distribution by Company Size and Location of Headquarters
  • Table 18.18 Medical Device Standalone CROs: Distribution by Type of Service Offered
  • Table 18.19 Clinical Trial Analysis: Distribution by Trial Registration Year, 2015-2020
  • Table 18.20 Clinical Trial Analysis: Distribution by Trial Status
  • Table 18.21 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 18.22 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 18.23 Clinical Trial Analysis: Geographical Distribution by Trial Status
  • Table 18.24 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 18.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 18.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Table 18.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 18.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
  • Table 18.29 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Location of Trial Site
  • Table 18.30 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2020)
  • Table 18.31 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Table 18.32 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
  • Table 18.33 Mergers and Acquisitions: Continent-wise Distribution
  • Table 18.34 Mergers and Acquisitions: Country-wise Distribution
  • Table 18.35 Mergers and Acquisitions: Ownership Change Matrix
  • Table 18.36 Mergers and Acquisitions: Distribution by Type of Company
  • Table 18.37 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 18.38 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Table 18.39 Survey Insights: Distribution of Respondents by Company Size
  • Table 18.40 Survey Insights: Distribution of Respondents by Location of Company Headquarters
  • Table 18.41 Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Table 18.42 Survey Insights: Distribution of Respondents by Type of Service Offered
  • Table 18.43 Survey Insights: Distribution of Respondents by Therapeutic Area
  • Table 18.44 Survey Insights: Distribution of Respondents by Average Number of Projects
  • Table 18.45 Survey Insights: Distribution of Respondents by Market Opportunity
  • Table 18.46 Overall Medical Device CRO Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.47 Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area (USD Billion)
  • Table 18.48 Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
  • Table 18.49 Medical Device CRO Market, 2020-2030: Distribution by Device Class (USD Billion)
  • Table 18.50 Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered (USD Billion)
  • Table 18.51 Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Service Offered (USD Billion)
  • Table 18.52 Medical Device CRO Market, 2020-2030: Distribution by Geography (USD Billion)
  • Table 18.53 Medical Device CRO Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.54 Medical Device CRO Market for Bone Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.55 Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.56 Medical Device CRO Market for CNS Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.57 Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.58 Medical Device CRO Market for Oncological Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.59 Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.60 Medical Device CRO Market for Pain Management Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.61 Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.62 Medical Device CRO Market for Sleeping Disorders in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.63 Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.64 Medical Device CRO Market for Class I Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.65 Medical Device CRO Market for Class II Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.66 Medical Device CRO Market for Class III Devices in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.67 Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.68 Medical Device CRO Market for Consulting Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.69 Medical Device CRO Market for Data Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.70 Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.71 Medical Device CRO Market for Other Clinical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.72 Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.73 Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.74 Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.75 Medical Device CRO Market for Other Preclinical Services in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.76 Medical Device CRO Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.77 Medical Device CRO Market for Bone Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.78 Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.79 Medical Device CRO Market for CNS Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.80 Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.81 Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.82 Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.83 Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.84 Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.85 Medical Device CRO Market for Sleeping Disorders in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.86 Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.87 Medical Device CRO Market for Class I Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.88 Medical Device CRO Market for Class II Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.89 Medical Device CRO Market for Class III Devices in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.90 Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.91 Medical Device CRO Market for Consulting Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.92 Medical Device CRO Market for Data Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.93 Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.94 Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.95 Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.96 Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.97 Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.98 Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.99 Medical Device CRO Market in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.100 Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.101 Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.102 Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.103 Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.104 Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.105 Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.106 Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.107 Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.108 Medical Device CRO Market for Sleeping Disorders in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.109 Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.110 Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.111 Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.112 Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.113 Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.114 Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.115 Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.116 Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.117 Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.118 Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.119 Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.120 Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.121 Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.122 Medical Device CRO Market in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.123 Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.124 Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.125 Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.126 Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.127 Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.128 Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.129 Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.130 Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.131 Medical Device CRO Market for Sleeping Disorders in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.132 Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.133 Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.134 Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.135 Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.136 Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.137 Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.138 Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.139 Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.140 Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.141 Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.142 Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.143 Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 18.144 Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 1MED SA
  • 2. 4Clinics
  • 3. A+ Science
  • 4. Abbott
  • 5. Abiogenesis Clinpharm
  • 6. Abond CRO (formerly known as QST Consultations)
  • 7. Absorption Systems
  • 8. ABX-CRO
  • 9. Acceliant
  • 10. Accell Clinical Research
  • 11. AccelLAB
  • 12. Accelovance
  • 13. Accredited Consultants
  • 14. AccuLab Life Sciences
  • 15. Accuprec Research Labs
  • 16. Accutest Research Laboratories
  • 17. Acorn Regulatory Consultancy Services
  • 18. Acrapack
  • 19. acromion
  • 20. aCROss Medical
  • 21. Activa Cro
  • 22. ADAX International
  • 23. Advanced Medical Research
  • 24. Advena
  • 25. Affinity Bio Partners
  • 26. Afra Pharma Consultant
  • 27. AGINKO Research
  • 28. AICROS
  • 29. AJW Technology Consultants
  • 30. AKRN Scientific Consulting
  • 31. Al Tamimi
  • 32. Allied Clinical Management
  • 33. Altair Clinical
  • 34. Altiora
  • 35. AMANO Clinical Consulting
  • 36. Amarex Clinical Research
  • 37. American Preclinical Services
  • 38. AmeRuss
  • 39. Amritt
  • 40. Amulet Capital Partners
  • 41. analyze & realize
  • 42. Andaman Medical
  • 43. anteris medical
  • 44. ANTRIX
  • 45. A-pharmaconsult
  • 46. apices
  • 47. APO Plus Station
  • 48. Appletree CI Group
  • 49. Arazy Group Consultants
  • 50. Archemin
  • 51. ARQon
  • 52. Asia Actual
  • 53. Asiatic Clinical Research
  • 54. ATLANSTAT
  • 55. AtoZ-CRO
  • 56. Auriga Research
  • 57. Australian Healthcare Solutions
  • 58. Auxilife Scientific Services
  • 59. Avania (formerly known as Factory CRO)
  • 60. AVANTI
  • 61. AVIAD Life Sciences
  • 62. Axonal-Biostatem
  • 63. Azelix
  • 64. Barons Medical Consulting
  • 65. Beaufort
  • 66. Beijing JRJ Science and Technology
  • 67. BIC Group
  • 68. BioAgile Therapeutics
  • 69. Biocodex Nordics
  • 70. Biomapas
  • 71. Biomedical Regulatory Consulting
  • 72. Biomedical Strategy
  • 73. Bioneeds
  • 74. BioPlan
  • 75. Biorasi
  • 76. Bioreg Services
  • 77. Bioscience
  • 78. Biotech Regulatory Solutions
  • 79. BioTeknica
  • 80. BiTrial Clinical Research
  • 81. BLAU Pharmaceutical Service
  • 82. BLS laboratories
  • 83. Boston Biomedical Associates
  • 84. Boston MedTech Advisors
  • 85. Boston Scientific
  • 86. Brandwood CKC
  • 87. Bridge Pharm
  • 88. BRIDGE PTS
  • 89. Cactus Life Sciences
  • 90. Cardinal Health
  • 91. CardioMed Device Consultants
  • 92. Cardiovascular European Research Center
  • 93. CARE Research
  • 94. Caritas Clinical
  • 95. CARSL Consulting
  • 96. Catalyst Regulatory Services
  • 97. Catawba Research
  • 98. Cato Research
  • 99. CBSET
  • 100. CC Clinical research Consultants
  • 101. C'en Al Research
  • 102. CERES
  • 103. Charles River Laboratories
  • 104. Chemical Inspection and Regulation Service
  • 105. Chiltern
  • 106. China Med Device
  • 107. Chris Freer Associates
  • 108. Citoxlab
  • 109. Clarivate Analytics
  • 110. ClinAudits
  • 111. ClinDatrix
  • 112. Clinical Device Group
  • 113. Clinical Research & Compliance Consulting
  • 114. Clinical Research Services (CRS)
  • 115. Clinical Trial Data Services
  • 116. CliniExperts
  • 117. Clinilabs
  • 118. Clinipace
  • 119. CLINIQAL™ International
  • 120. Clinlogix
  • 121. Clinmark
  • 122. ClinMed Pharma
  • 123. Clinnex
  • 124. ClinSync
  • 125. Cmed
  • 126. CMIC Group
  • 127. CMX Research
  • 128. Cobridge
  • 129. Commercial Eyes
  • 130. ComplianceAcuity
  • 131. CONET
  • 132. Consultys
  • 133. Convex
  • 134. Costello Medical
  • 135. Courante Oncology
  • 136. Covance
  • 137. CPS Cortex
  • 138. Criterium
  • 139. Cromos Pharma
  • 140. CROMSOURCE
  • 141. CROS NT
  • 142. Crown CRO
  • 143. CSSi LifeSciences™
  • 144. CTI
  • 145. CTNT
  • 146. CurAccel
  • 147. Cvigilance
  • 148. CW Research & Management
  • 149. CYA Medical Device Consulting
  • 150. Dalia Givony, Regulatory & Clinical Consulting
  • 151. Databean
  • 152. Datapharm Australia
  • 153. De Groot Technical Services
  • 154. DEKRA
  • 155. Denothex
  • 156. Devicia
  • 157. DFS Pharma
  • 158. DH RegSys
  • 159. dicentra
  • 160. DKSH Marketing Services Spain
  • 161. dMed
  • 162. dn8 collaborate
  • 163. Donawa Lifescience Consulting
  • 164. Dor Pharmaceutical Services
  • 165. Dove Quality Solutions
  • 166. DP Clinical
  • 167. DSA Consultants
  • 168. DZS Clinical Services
  • 169. EAS Consulting Group
  • 170. EG Mont
  • 171. Element
  • 172. Emergent Clinical Consulting
  • 173. En Pointe Clinical Research
  • 174. Engel, Hellyer & Partners
  • 175. e-novex
  • 176. EPIC CRO Research
  • 177. Essilor
  • 178. ESTERN Medical
  • 179. Ethicare
  • 180. EuDRAcon
  • 181. Eurofins Medical Device Testing
  • 182. Evidilya
  • 183. Exalon
  • 184. FDAInsight
  • 185. FGK Clinical Research
  • 186. Firma Clinical Research
  • 187. Five Corners
  • 188. FMD K&L
  • 189. Focal Point Research
  • 190. Fountain Medical Development
  • 191. Fresenius Medical Care
  • 192. Frestedt
  • 193. Freyr
  • 194. Gateway
  • 195. GCP-Service International
  • 196. GE Healthcare
  • 197. genae
  • 198. Genco Medical
  • 199. Genelife Clinical Research
  • 200. Genpact
  • 201. George Clinical
  • 202. Getz Healthcare
  • 203. GKM
  • 204. Global Center for Medical Innovation
  • 205. Global Pharma Tek
  • 206. Global Regulatory Affairs
  • 207. Global Regulatory Partners
  • 208. Global Regulatory Services
  • 209. Grove Group
  • 210. Gsap
  • 211. Hangzhou Tigermed Consulting
  • 212. Healthcare International Partners
  • 213. HealthLink
  • 214. Hilbert Paradox
  • 215. Hinge Clinica
  • 216. HungaroTrial
  • 217. I3CGLOBAL
  • 218. IBEX Preclinical Research
  • 219. ICBio
  • 220. ICON
  • 221. ICRC-Weyer
  • 222. ICTA
  • 223. IDConic
  • 224. Illingworth Research Group
  • 225. IMARC Research
  • 226. Inamed
  • 227. Innomar Strategies (a part of AmerisourceBergen)
  • 228. Inotiv
  • 229. InrexTest
  • 230. Integrated Resource
  • 231. International HealthCare
  • 232. Intertek Group
  • 233. Ipsum
  • 234. IQVIA
  • 235. Iris Pharma
  • 236. Ironstone Product Development
  • 237. IRW
  • 238. ISA HEALTH
  • 239. ITEC Services
  • 240. iuvo
  • 241. IVD Consultants
  • 242. IVDeology
  • 243. IZiel Healthcare
  • 244. J. Knipper
  • 245. Japan MDC
  • 246. Johnson & Johnson
  • 247. JSS Medical Research
  • 248. Jyton
  • 249. KCR
  • 250. KCRI
  • 251. KD&A
  • 252. Ken Block Consulting
  • 253. Kensington Swan
  • 254. Keystone Regulatory Services
  • 255. Kinapse
  • 256. KLIFO
  • 257. Knoell
  • 258. Kobridge Consulting
  • 259. KPS Clinical Services
  • 260. L.S Marketing & Registration
  • 261. LabCorp
  • 262. Lahav C.R.O
  • 263. Lambda Therapeutic Research
  • 264. Larix
  • 265. Lean RAQA
  • 266. Leon Research
  • 267. Li-Med RA & QA Experts
  • 268. Linical Accelovance Group
  • 269. LINK Medical
  • 270. Lionbridge
  • 271. Liveon Biolabs
  • 272. LNAge
  • 273. Macnair Consultants
  • 274. Made Consulting
  • 275. MakroCare
  • 276. Malca Chen-Zion
  • 277. MANDALA International
  • 278. MasterControl
  • 279. MAXIS
  • 280. McCarthy Consultant Services
  • 281. MD101 Consulting
  • 282. MD-Clinicals
  • 283. mdi Consultants
  • 284. mdi Europa
  • 285. MDP Solutions
  • 286. MED Institute
  • 287. Medanex Clinic
  • 288. Medelis
  • 289. Medfiles
  • 290. Medical Equipment Compliance Associates
  • 291. Medicomp
  • 292. MedicSense
  • 293. Medidee
  • 294. MediqTrans
  • 295. MEDITRIAL
  • 296. Meditrial MedTech Universe
  • 297. MedNet
  • 298. Medpace
  • 299. MedPass International
  • 300. MedQ Consultants
  • 301. Medtronic
  • 302. MedVigil
  • 303. Medvinbio Labs
  • 304. Mene Research
  • 305. Mericon
  • 306. Meshayu Consultants
  • 307. MethodSense
  • 308. Metrics Research
  • 309. MIC Medical
  • 310. Micren Healthcare
  • 311. Mid-Link Consulting
  • 312. MileStone Research
  • 313. Mn Solutions
  • 314. Mobius Medical
  • 315. Morley Research Consortium
  • 316. Morula HealthTech
  • 317. MPI Research
  • 318. Musculoskeletal Clinical Regulatory Advisers
  • 319. NAMSA
  • 320. Navitas Life Sciences
  • 321. NCGS
  • 322. Nelson Labs
  • 323. NEOMED Services
  • 324. Neometrix Consulting
  • 325. Neopharm
  • 326. Neox Clinical Research
  • 327. Neozene
  • 328. Nerac
  • 329. New England Research Institutes
  • 330. Noble Life Sciences
  • 331. Northlane Capital Partners
  • 332. Novartis
  • 333. NovaTrials
  • 334. Novem Healthcare
  • 335. Novum
  • 336. NoyMed
  • 337. NSF International
  • 338. Nuvisan Pharma Services
  • 339. Nyprax Pharma
  • 340. O4 Research
  • 341. Obelis Group
  • 342. Odelle Technology
  • 343. Onorach
  • 344. Operon Strategist
  • 345. OPIS
  • 346. Optimal Pharm/Tox Consulting
  • 347. Optimal Research
  • 348. Optimapharm
  • 349. Ora
  • 350. Osmunda
  • 351. OThree Consulting
  • 352. Pace Analytical
  • 353. Pacific BioLabs
  • 354. Pacific Bridge Medical
  • 355. Pacific Clinical Research Group
  • 356. Pamplona Capital Management
  • 357. PAREXEL International
  • 358. PaxMed International
  • 359. Pearl Pathways
  • 360. Pepgra
  • 361. Perfect Pharmaceuticals Consultants
  • 362. Perfection-CRO
  • 363. Pharmaceutical Regulatory Services
  • 364. Pharmaceutical Solutions
  • 365. Pharmahungary Group
  • 366. PharmaLex
  • 367. PharmaMed Research
  • 368. Pharmaseed
  • 369. PharmDedict
  • 370. PharmEng Regulatory Affairs
  • 371. PharmOut
  • 372. Phidea Group
  • 373. Pilgrim Quality Solutions
  • 374. Pine Lake Laboratories
  • 375. Pivotal
  • 376. PMI Preclinical
  • 377. PPD
  • 378. PQE Group
  • 379. PRA Health Sciences
  • 380. PRADO
  • 381. PRC Clinical
  • 382. Precision Medicine Group
  • 383. Preclinical Medevice Innovations
  • 384. PreClinical Pathfinder
  • 385. PreClinical Research Services
  • 386. Premier Research
  • 387. Professionals Regulatory Affairs
  • 388. Profil
  • 389. Promedica International
  • 390. ProMedoss
  • 391. ProPharma Group
  • 392. Prosoft Clinical
  • 393. ProTrials
  • 394. Proxima Clinical Research
  • 395. PRSG - Pharmaceutical and Regulatory Services
  • 396. Q&R Canada
  • 397. QA Consulting
  • 398. QAdvis
  • 399. Qmed Consulting
  • 400. Qserve Group
  • 401. Q-Trials
  • 402. Qualitiso
  • 403. Quality and Compliance Consulting
  • 404. Qualtech Consulting
  • 405. Quanticate
  • 406. QUNIQUE
  • 407. R & C Consulting
  • 408. R&G PharmaStudies
  • 409. R.G.L Research
  • 410. RAMED
  • 411. Ratos
  • 412. RCQ Solutions
  • 413. RCRI (now a part of Covance)
  • 414. Reg-Affairs & QualiPractixis
  • 415. Regulatory and Quality Solutions
  • 416. Regulatory Compliance Associates
  • 417. Regulatory Insight
  • 418. Reimbursement Strategies
  • 419. Research Professionals
  • 420. Rho
  • 421. RJR Consulting
  • 422. RMF Clinical
  • 423. Rook Quality Systems
  • 424. RQMIS
  • 425. RQSolutions
  • 426. RTI Health Solutions
  • 427. Scandinavian CRO
  • 428. Scandinavian Regulatory Services AB
  • 429. SCIderm
  • 430. Scope International
  • 431. SeerPharma
  • 432. Sentez-CRO
  • 433. Seoul CRO
  • 434. SEQ
  • 435. SGS
  • 436. Shanghai QiSheng Business Consulting
  • 437. Shenzhen Advanced Medical Services
  • 438. Sidley Austin
  • 439. Siemens
  • 440. Simmons & Simmons
  • 441. Sipra Labs
  • 442. Sixmurs Group
  • 443. SMS-oncology
  • 444. Southern Star Research
  • 445. Sparta Systems
  • 446. SPharm
  • 447. SPRIM Advanced Life Sciences
  • 448. StarFish Medical
  • 449. STATKING Clinical Services
  • 450. SteriPack Contract Manufacturing
  • 451. SterlingBio
  • 452. Strategic Compliance International
  • 453. StrugoPharm
  • 454. Stryker
  • 455. Sumika Chemical Analysis Service
  • 456. SunFlare
  • 457. Surpass
  • 458. Surpass-Silicon Valley
  • 459. Symbion Research
  • 460. Symbioteq
  • 461. Syneos Health
  • 462. Syntax
  • 463. Synteract
  • 464. TAB Clinical
  • 465. Target Health
  • 466. TCA Clinical Research
  • 467. TechnoSTAT
  • 468. TentaMedix (formerly MicroMol)
  • 469. The Clinical Trial Company
  • 470. The CRO Group
  • 471. The Medical Affairs Company
  • 472. The Weinberg Group
  • 473. THEMA
  • 474. Theo Manufacturing
  • 475. Theorem Clinical Research
  • 476. TheraGenesis
  • 477. ThreeWire
  • 478. Toxikon
  • 479. TPIreg
  • 480. TransPerfect Life Sciences
  • 481. Trial Form Support International
  • 482. TriMetis
  • 483. Turacoz Healthcare Solutions
  • 484. TÜV SÜD - Healthcare & Medical Devices
  • 485. Ulmer Ventures
  • 486. Underwriters Laboratories
  • 487. Unikal Consultants
  • 488. Vantage BioTrials
  • 489. Vantage Consulting
  • 490. Venn Life Sciences
  • 491. Veristat
  • 492. Vimta
  • 493. vivo Science (a Texcell company)
  • 494. Vivotecnia
  • 495. Voler Biotech Consulting
  • 496. Vyomus Consulting
  • 497. WCCT Global
  • 498. WDB Holdings
  • 499. Wipro
  • 500. Wonderville
  • 501. WOODLEY BIOREG
  • 502. WuXi AppTec
  • 503. ZEINCRO
  • 504. Zi-Medical
  • 505. Zimmer Biomet
  • 506. Zwiers Regulatory Consultancy